Trial · NCT02605174
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Headache Pain Free at 2 Hours Post Dose | 2 hours post dose | The percentage of participants defined as mild, moderate, or severe headache pain becoming none. |
| Primary | Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free | 2 hours post dose | The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent. |
| Other | Percentage of Participants With Headache Relief | 2 hours post dose | The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none. |
| Other | Number of Participants With Headache Recurrence | From 2 Hours Post Dose Up to 48 Hours | The number of participants with headache recurrence (moderate or severe at baseline which became pain-free at 2 hours post dose and worsened again up to 48 hours post dose) |
| Other | Percentage of Participants Use of Rescue Medication | 2 hours post dose | The percentage of participants who used rescue medication. |
| Other | Percentage of Participants Use of Rescue Medication | From 2 Hours Post Dose Up to 24 Hours | The percentage of participants who used rescue medication. |
| Other | Percentage of Participants Use of Rescue Medication | From 24 Post Dose Up to 48 Hours | The percentage of participants who used rescue medication. |
| Other | Percentage of Participants Nausea Free | 2 hours post dose | The percentage of participant without nausea. |
| Other | Percentage of Participants With Phonophobia Free | 2 hours post dose | The percentage of participants without phonophobia. |
| Other | Percentage of Participants With Photophobia Free | 2 hours post dose | The percentage of participants without photophobia. |
| Other | Percentage of Participants With Resource Utilization | 6 Months Prior to Enrolling in Study to End of Study (Up to 11 Weeks) Within 7 Days of Treating a Single Migraine Attack | Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study |
| Other | Number of Participants With Treatment Emergent Events | From Baseline Up to End of Study (Up to 11 Weeks) | Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02605174/registered